Consistent with previous reports, we found that the circulating level and local expression of IGFBP2 were positively correlated with gefitinib resistance in NSCLC, while no correlation between IGFBP2 level and TNM stage of lung cancer was found based on TCGA database. This evidence concerns the gene IGFBP2 and non-small cell lung carcinoma.